Amino acid formulations useful for treating diarrhea in a subject in need thereof are described herein. Such amino acid formulations and methods comprising administering same to a subject are useful for treating diarrhea, particularly diarrhea caused by or associated with bacterial infections wherein secretagogue-stimulated anion secretion from the intestinal crypt contributes to at least one symptom of diarrhea in the subject. Use of these amino acid formulations for the treatment of diarrhea in general or diarrhea associated with secretagogue-stimulated anion secretion from the intestinal crypt are encompassed herein, as are their use in the preparation of a medicament for the treatment of diarrhea in general or diarrhea associated with secretagogue-stimulated anion secretion from the intestinal crypt.

Amino acid formulations useful for treating diarrhea in a subject in need thereof are described herein. Such amino acid formulations and methods comprising administering same to a subject are useful for treating diarrhea, particularly diarrhea caused by or associated with bacterial infections wherein secretagogue-stimulated anion secretion from the intestinal crypt contributes to at least one symptom of diarrhea in the subject. Use of these amino acid formulations for the treatment of diarrhea in general or diarrhea associated with secretagogue-stimulated anion secretion from the intestinal crypt are encompassed herein, as are their use in the preparation of a medicament for the treatment of diarrhea in general or diarrhea associated with secretagogue-stimulated anion secretion from the intestinal crypt.

This invention relates to compositions for use in the treatment of diabetes, for example type-2 diabetes; obesity; and/or metabolic syndrome. Specifically, the invention relates to a composition for use in the treatment of diabetes, the composition comprising at least one of diindolylmethane; indole-3-carbinol; embelin; [6]-gingerol; and [6]-shogaol, or combinations each thereof. Also disclosed is use in the treatment of obesity and use in the treatment of metabolic syndrome.

This invention relates to compositions for use in the treatment of diabetes, for example type-2 diabetes; obesity; and/or metabolic syndrome. Specifically, the invention relates to a composition for use in the treatment of diabetes, the composition comprising at least one of diindolylmethane; indole-3-carbinol; embelin; [6]-gingerol; and [6]-shogaol, or combinations each thereof. Also disclosed is use in the treatment of obesity and use in the treatment of metabolic syndrome.

This invention relates to compositions for use in the treatment of diabetes, for example type-2 diabetes; obesity; and/or metabolic syndrome. Specifically, the invention relates to a composition for use in the treatment of diabetes, the composition comprising at least one of diindolylmethane; indole-3-carbinol; embelin; [6]-gingerol; and [6]-shogaol, or combinations each thereof. Also disclosed is use in the treatment of obesity and use in the treatment of metabolic syndrome.

A method for treating metabolic disorders in non-infant includes administering to an obese non-infant human during a treatment period an effective amount of a mixture of two or more synthetic neutral human milk oligosaccharides (HMOs) selected from 2′-fucosyllactose (2′FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-fucopentaose I (LNFP-I), lacto-N-tetraose (LNT), and lacto-N-neotetraose (LNnT), and optionally one or more excipients. The method further includes increasing in the gastrointestinal microbiota of the non-infant human during the treatment period, the relative abundance of Bifidobacterium adolescentis and reducing in the non-infant human during the treatment period, a precursor condition for a metabolic disorder associated with development of one or more of obesity-induced pre-diabetes and type 2 diabetes, the precursor condition selected from gut permeability, metabolic endotoxemia, low-grade metabolic inflammation, and body fat percentage.

A method for treating metabolic disorders in non-infant includes administering to an obese non-infant human during a treatment period an effective amount of a mixture of two or more synthetic neutral human milk oligosaccharides (HMOs) selected from 2′-fucosyllactose (2′FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-fucopentaose I (LNFP-I), lacto-N-tetraose (LNT), and lacto-N-neotetraose (LNnT), and optionally one or more excipients. The method further includes increasing in the gastrointestinal microbiota of the non-infant human during the treatment period, the relative abundance of Bifidobacterium adolescentis and reducing in the non-infant human during the treatment period, a precursor condition for a metabolic disorder associated with development of one or more of obesity-induced pre-diabetes and type 2 diabetes, the precursor condition selected from gut permeability, metabolic endotoxemia, low-grade metabolic inflammation, and body fat percentage.

Compositions comprising microbiome regulators are provided, as well as methods of using the same for the modulation of the human microbiota and to treat or prevent related diseases, disorders, or conditions.

Compositions comprising microbiome regulators are provided, as well as methods of using the same for the modulation of the human microbiota and to treat or prevent related diseases, disorders, or conditions.

The present invention relates to an enteral sustained-release sugar alcohol additive including an inner layer structure and an outer layer structure. The inner layer structure contains components of xylitol and agar, and the outer layer structure contains components of carrageenan or gellan gum or xanthan gum or guar gum, vitamin B12, L-arabinose, and fermented bifidobacterium or fermented propionibacterium or fermented lactobacillus. The present invention further provides a method of preparing an enteral sustained-release sugar alcohol additive and an application thereof. In the present invention, by compounding xylitol, L-arabinose and vitamin B12, directional regulation of intestinal microorganisms can be achieved and high concentration synthesis of propionate in the intestine can be realized.